Table 3.
Ongoing Trials of Teclistamab in Myeloma
| Agent(s) | Disease Setting | Phase | Clinical Trial ID | Status |
|---|---|---|---|---|
| Teclistamab | RRMM, ≥3 prior LOT | 1/2 | NCT04557098 | Recruiting |
| Teclistamab vs Rd | High risk smoldering myeloma | 2 | NCT05469893 | Recruiting |
| Teclistamab vs PVd or Kd | RRMM, 1–3 prior LOT | 3 | NCT05572515 | Recruiting |
| Teclistamab or talquetamab with PD-1 inhibitor | RRMM, no further established therapies | 1 | NCT05338775 | Recruiting |
| Teclistamab with various therapies (multi-armed): daratumumab, lenalidomide, pomalidomide, bortezomib, nirogacestat | NDMM or RRMM | 1 | NCT04722146 | Active, not recruiting |
| Maintenance teclistamab with lenalidomide and teclistamab alone vs lenalidomide after ASCT | NDMM | 3 | NCT05243797 | Recruiting |
| Teclistamab with daratumumab with/without pomalidomide and talquetamab with daratumumab | RRMM, ≥3 prior LOT | 1 | NCT04108195 | Active, not recruiting |
| Teclistamab with daratumumab vs DPd or DVd | RRMM, 1–3 prior LOT | 3 | NCT05083169 | Recruiting |
| Teclistamab with daratumumab, lenalidomide, dexamethasone with/without bortezomib | NDMM | 2 | NCT05695508 | Recruiting |
| Teclistamab with daratumumab, lenalidomide vs DRd | NDMM | 3 | NCT05552222 | Recruiting |
| Teclistamab with talquetamab | RRMM, no further established therapies | 1/2 | NCT04586426 | Recruiting |
Abbreviations: Rd, lenalidomide, dexamethasone, PVd, pomalidomide, bortezomib, dexamethasone, Kd, carfilzomib, dexamethasone, DPd, daratumumab, pomalidomide, dexamethasone, DVd, daratumumab, bortezomib, dexamethasone, DRd, daratumumab, lenalidomide, dexamethasone.